<DOC>
	<DOCNO>NCT00004031</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Radiation therapy use high-energy x-rays damage cancer cell . Peripheral stem cell transplantation may allow doctor give high dos chemotherapy radiation kill cancer cell . It yet know whether chemoradiotherapy plus peripheral stem cell transplantation effective combination chemotherapy alone treat non-Hodgkin 's lymphoma . PURPOSE : This randomized phase III trial study chemoradiotherapy peripheral stem cell transplantation see well work compare combination chemotherapy treat patient stage II , stage III , stage IV non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>SWOG-9704 Chemoradiotherapy Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy Treating Patients With Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Compare overall survival progression-free survival patient intermediate- high-grade non-Hodgkin 's lymphoma treat high-dose chemoradiotherapy autologous peripheral blood stem cell transplantation ( APBSCT ) vs conventional dose cyclophosphamide , doxorubicin , vincristine , prednisone ( CHOP ) ( CHOP plus rituximab CD20+ disease ) possible late APBSCT . - Compare toxic effect regimens patient population . OUTLINE : This randomize study . Patients stratify accord disease risk ( intermediate-high v high ) . Patients receive CHOP chemotherapy comprise cyclophosphamide IV 15 minute , doxorubicin IV , vincristine IV day 1 oral prednisone day 1-5 . Patients CD20-positive disease also receive rituximab IV day 1 ( day 0 course 1 ) . Treatment repeat every 3 week 5 course absence disease progression unacceptable toxicity . Within 35 day complete fifth course , patient partial complete response randomize one two treatment arm . - Arm I : Patients receive CHOP ( CHOP plus rituximab [ CHOP-R ] ) . Treatment repeat every 3 week 3 additional course . After completion chemotherapy , patient encourage undergo harvest peripheral blood stem cell ( PBSC ) possible use time relapse . After completion 8 course , patient receive additional therapy disease progression biopsy-proven disease . - Arm II : Patients receive one additional course CHOP/CHOP-R follow filgrastim ( G-CSF ) , sargramostim ( GM-CSF ) , colony-stimulating factor use singly combination accord center preference . PBSC harvest select CD34+ cell . Patients age 61 receive one two preparative regimen : total body irradiation ( TBI ) -based regimen comprise irradiation administer twice daily day -8 -5 , etoposide IV 4 hour day -4 , cyclophosphamide IV 1 hour day -2 OR carmustine IV 2 hour day -6 -4 etoposide cyclophosphamide TBI-based regimen . Patients age 61 65 receive augment regimen comprise carmustine , etoposide , cyclophosphamide . Patients receive involved field radiotherapy prior preparative regimen biopsy-proven residual bulk disease discretion center . PBSC reinfused 36-48 hour completion cyclophosphamide . If bone marrow PBSC harvest , bone marrow reinfused day 0 PBSC reinfused either day follow day . Patients follow every 6 month 2 year annually thereafter . PROJECTED ACCRUAL : Approximately 360 patient ( least 135 per treatment arm ) accrue study within 5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven intermediate highgrade nonHodgkin 's lymphoma Ann Arbor classification `` bulky '' stage II , III , IV Must classify highintermediate highrisk accord International Age Adjusted Index Bidimensionally measurable disease No lymphoblastic , transform , mantle cell lymphomas No CNS involvement lymphoma CD20 status confirm immunocytochemistry flow cytometry Must either bilateral unilateral bone marrow aspiration biopsy â‰¥ 42 day first course cyclophosphamide , doxorubicin , vincristine , prednisone ( CHOP ) therapy ( CHOP plus rituximab [ CHOPR ] CD20+ disease ) OR within 42 day prior registration CHOP/CHOPR therapy begin Must bilateral bone marrow aspiration biopsy within 28 day randomization Bone marrow involvement lymphoma allow , provide improvement least 50 % use evaluable site disease No prior lymphoma , Hodgkin 's lymphoma , myelodysplastic syndrome , leukemia NOTE : A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age : 15 65 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) No nonlymphomarelated hepatic dysfunction Renal : Creatinine great 2 time ULN Creatinine clearance least 60 mL/min No nonlymphomarelated renal dysfunction No history grade 3 hemorrhagic cystitis due cyclophosphamide Cardiovascular : No coronary artery disease , cardiomyopathy , congestive heart failure , dysrhythmia require therapy MUGA scan 2D echocardiogram require patient 's history questionable Ejection fraction normal Pulmonary : DLCO FEV_1 least 60 % predict Other : Not pregnant nursing Fertile patient must use effective contraception HIV negative No malignancy within past 5 year except basal cell squamous cell skin cancer carcinoma situ cervix No allergy etoposide No active bacterial , fungal , viral infection PRIOR CONCURRENT THERAPY : Biologic therapy : No prior monoclonal antibody therapy lymphoma except include single course CHOP/CHOPR Chemotherapy : No prior chemotherapy lymphoma except single course CHOP/CHOPR* NOTE : *Prednisone corticosteroid consider prior chemotherapy Endocrine therapy : See Chemotherapy Prior corticosteroid allow Radiotherapy : No prior radiotherapy lymphoma No prior thoracic radiotherapy radiotherapy great 2,000 cGy site Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>contiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>contiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
</DOC>